Literature DB >> 17622742

Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice.

Ryan M Fryer1, Pamela A Rakestraw, Masaki Nakane, Doug Dixon, Patricia N Banfor, Kristin A Koch, J Ruth Wu-Wong, Glenn A Reinhart.   

Abstract

BACKGROUND/AIMS: Vitamin D receptor activators (VDRAs) may suppress renin expression and VDR-mediated renin inhibitors may offer a novel mechanism to control the RAS.
METHODS: We delineated the effects of paricalcitol and calcitriol on PTH, renin, and iCa(2+) in C57/BL6 mice administered vehicle, paricalcitol, or calcitriol (0.01, 0.03, 0.10, 0.33, 1.0 microg/kg s.c.) 3 days/week for 9 days.
RESULTS: Paricalcitol produced PTH suppression from 0.03 to 1.0 microg/kg (values between 9.7 +/- 3.3 and 20.7 +/- 4.7 pg/ml; vehicle = 88.0 +/- 16.9) and elicited dose-dependent reductions in renin/GAPDH expression at 0.33 and 1.0 microg/kg (0.037 +/- 0.002, 0.027 +/- 0.003; vehicle = 0.054 +/- 0.003) but produced no increases iCa(2+) at any dose tested. Calcitrol produced PTH suppression at all doses tested (between 6.4 +/- 1.2 and 29.5 +/- 17.2 pg/ml) and renin suppression at 0.10, 0.33, and 1.0 microg/kg (0.029 +/- 0.002, 0.031 +/- 0.003, and 0.038 +/- 0.02). However, at 0.33 and 1.0 mg/kg, calcitriol produced increases iCa(2+) (1.31 +/- 0.03 and 1.48 +/- 0.02 mmol/l; vehicle = 1.23 +/- 0.02 mmol/l).
CONCLUSIONS: Paricalcitol produces significant, dose-dependent suppression of renin expression in the absence of hypercalcemia at doses 10-fold above those necessary for PTH suppression. Calcitriol also produced suppression of renin at doses at least 10-fold above those required for PTH suppression, but increases in iCa(2+) were observed at doses only 3-fold above those necessary to elicit renin suppression. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622742     DOI: 10.1159/000104875

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  20 in total

1.  Vitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis and modulation of autophagy.

Authors:  Tianbao Yao; Xiaoying Ying; Yichao Zhao; Ancai Yuan; Qing He; Huan Tong; Song Ding; Junling Liu; Xu Peng; Erhe Gao; Jun Pu; Ben He
Journal:  Antioxid Redox Signal       Date:  2015-01-14       Impact factor: 8.401

Review 2.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

Review 3.  The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system.

Authors:  Marcelo Ferder; Felipe Inserra; Walter Manucha; León Ferder
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-30       Impact factor: 4.249

Review 4.  Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?

Authors:  Patrick H Biggar; Orfeas Liangos; Holger Fey; Vincent M Brandenburg; Markus Ketteler
Journal:  Pediatr Nephrol       Date:  2010-04-27       Impact factor: 3.714

Review 5.  Vitamin D and Calcimimetics in Cardiovascular Disease.

Authors:  Kenneth Lim; Takayuki Hamano; Ravi Thadhani
Journal:  Semin Nephrol       Date:  2018-05       Impact factor: 5.299

Review 6.  Vitamin D and diabetic nephropathy.

Authors:  Yan Chun Li
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

7.  Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction.

Authors:  Soochan Bae; Sylvia S Singh; Hyeon Yu; Ji Yoo Lee; Byung Ryul Cho; Peter M Kang
Journal:  J Appl Physiol (1985)       Date:  2013-02-21

8.  Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.

Authors:  Yan Zhang; Dilip K Deb; Juan Kong; Gang Ning; Yurong Wang; George Li; Yunzi Chen; Zhongyi Zhang; Stephen Strugnell; Yves Sabbagh; Cynthia Arbeeny; Yan Chun Li
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-17

9.  Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy.

Authors:  Xiaoyue Tan; Weichun He; Youhua Liu
Journal:  Kidney Int       Date:  2009-09-16       Impact factor: 10.612

Review 10.  Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Authors:  Diego Brancaccio; Jürgen Bommer; Daniel Coyne
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.